Skip to content

Augmented Sensory in Cancer-Related Neuropathic Patients

Impact of Augmented Sensory Feedback on Motor Control and Risk of Falling in Cancer-Related Neuropathic Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07027215
Enrollment
40
Registered
2025-06-18
Start date
2024-01-20
Completion date
2024-05-30
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physical Therapy

Brief summary

this research studied the effect of augmented sensory feedback program on motor control and risk of falling in patient with CIPN.

Detailed description

Design: A randomized control trial was conducted to investigate the impact of augmented sensory feedback paradigm on motor control and risk of falling in patient with Chemotherapy-induced peripheral neuropathy. Data were collected pre and post treatment from out-patient clinic of the Faculty of Medicine and Faculty of Physical Therapy South Valley University, between January 2023and March 2024. The study was approved by the ethical committee of the Faculty of Physical Therapy, South Vally University, Egypt. The study protocol was explained in detail to every patient and signed written consent was obtained before participation. Participants: forty female patients with CIPN were recruited from out-patient clinic of the Faculty of Medicine and Faculty of Physical Therapy South Valley University, between January 2023and March 2024.

Interventions

COMBINATION_PRODUCTselected physical therapy program as arm excercises

selected physical therapy program only. The program consisted of (core exercises, AROM exercises, and stretching exercises for LL for 18 sessions every other day, over 6 weeks

COMBINATION_PRODUCTGradual Intermittent pneumatic compression therapy (IPC),Balance excercises.PNF technique

PNF technique

Sponsors

Isra University, Jordan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Forty female with age from 35-60 years * clinically diagnosed with CIPN after recovery from stage I or II breast cancer * The strength at the toes, ankles, knees, and hips, as determined by manual muscle tests, of at least 3/5. * The patients can walk independently with or without any assistive devices.

Exclusion criteria

* Patients with a history of hereditary peripheral neuropathy * Diseases that may contribute to peripheral nerve damage, such as diabetes or renal insufficiency, alcohol abuse, HIV, and vasculitis. * Patient who had central or peripheral neurologic disease, brain or spinal cord metastases * Orthopedic problems influencing gait, or foot ulcer at the moment of intake. * Patients with vestibular or neurological problems influencing gait parameters * Subjects who had participated in regular exercise, as defined as 150 min of light-to-moderate intensity exercise per week over the past year, were excluded from this trial.

Design outcomes

Primary

MeasureTime frameDescription
improvement of balance which was assessed by fall risk scaleone and half monthimprovement in feet sensitivity and motor control and risk of falling in both groups in favor of the study group.
Stability measuresone and half monthpostural stability was measured using a Biodex Balance System SD (950-440 with version 4.X software)
Sensory feedbackone and half monthSensory feedback was assessed by using Semmes-Weinstein monofilament (SWM)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026